Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?

Expert Rev Mol Diagn. 2018 Jan;18(1):1-3. doi: 10.1080/14737159.2018.1386558. Epub 2017 Oct 6.

Authors

Jeanne Tie^{1

2

3

4}, Christine Semira¹, Peter Gibbs^{1

2

3

4}

Affiliations

¹ a Division of Systems Biology and Personalised Medicine , Walter and Eliza Hall Institute of Medical Research , Melbourne , Australia.
² b Faculty of Medicine, Dentistry and Health Sciences , University of Melbourne , Melbourne , Australia.
³ c Department of Medical Oncology , Western Health , Melbourne , Australia.
⁴ d Department of Medical Oncology , Peter MacCallum Cancer Centre , Melbourne , Australia.

PMID: 28954554
DOI: 10.1080/14737159.2018.1386558

No abstract available

Keywords: Circulating tumor DNA; biomarker; colorectal cancer; prognosis; rectal cancer.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor*
Chemotherapy, Adjuvant
Circulating Tumor DNA*
Clinical Decision-Making
Combined Modality Therapy
Disease Management
Humans
Neoplasm Staging
Postoperative Care*
Rectal Neoplasms / diagnosis*
Rectal Neoplasms / therapy*

Substances

Biomarkers, Tumor
Circulating Tumor DNA